For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Keyword

Understanding patient experience in Europe: The first Global Lung Cancer Coaliti...

Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England

Understanding patient experience in Europe: The first Global Lung Cancer Coalition Patient Experience Survey ( Vanessa Beattie - Lung Cancer Nursing UK, Solihull, England )

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients w...

Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK

CONVERT trial: Patterns of relapse following thoracic radiotherapy in patients with limited-stage SCLC ( Dr Robin Portner - The Christie NHS Foundation Trust, Manchester, UK )

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...

Dr Martina Lorenzi - University of Padua, Padua, Italy

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the real-world ( Dr Martina Lorenzi - University of Padua, Padua, Italy )

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...

Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA

CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable NSCLC ( Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA )

Phase III randomised trial comparing tebentafusp with investigator’s choice in f...

Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany

Phase III randomised trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma ( Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany )

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

SMMART Program: A multi-omics tumour board with a focus on breast cancer

Dr Ben Kong - Oregon Health & Science University, Portland, USA

SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutan...

Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in p...

Prof Georgina Long - University of Sydney, Sydney, Australia

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocell...

Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA

Safety and efficacy of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma ( Prof Richard Finn - Geffen School of Medicine at UCLA, Los Angeles, USA )

More from ecancer